Developing a Human Cell Model for Fragile X Syndrome Using Direct Reprogramming

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.advisor Connor, B en
dc.contributor.author Edwards, Nicole en
dc.date.accessioned 2017-05-29T21:34:47Z en
dc.date.issued 2017 en
dc.identifier.uri http://hdl.handle.net/2292/33152 en
dc.description Full text is available to authenticated members of The University of Auckland only. en
dc.description.abstract A comprehensive view of the mechanisms underpinning the neurodevelopmental disorder Fragile X Syndrome (FXS) is lacking owing to limited access to relevant human cell models. Therefore, the development of tractable and representative models of human neurodevelopmental disorders is crucial to our ability to draw physiologically relevant conclusions about the mechanisms of FXS pathogenesis. Ideally, experimental models of this disorder would recapitulate the cellular and molecular mechanisms underlying the phenotypic characteristics of FXS as they are manifested in humans. Additionally, both the genetic and phenotypic characteristics of this disorder would be represented within FXS-associated cell types at defined stages of neuronal development that are relevant to FXS progression. The use of cell reprogramming to generate FXS patient-derived human neural stem/precursor cells provides a powerful platform to elucidate the mechanistic underpinnings of aberrant neurodevelopmental phenotypes as they occur in humans. Therefore, the aim of this study was to establish our capability to generate FXS patientderived neural progenitor cells (iNPs) and subsequently neurons by direct reprogramming to a neural progenitor state. Furthermore, direct reprogramming of FXS patient-derived fibroblasts would be achieved using a novel chemically modified mRNA gene delivery system advanced by the Neural Reprogramming and Repair laboratory. This study demonstrated that diverse cell populations positive for both neural progenitor and neuronal markers can be derived directly from somatic cells by SOX2/PAX6-SNIM® RNA mediated reprogramming. Importantly, reprogrammed FXS cell lines exhibited transcriptional and phenotypic differences, which may be suggestive of early FXS-associated mechanisms occurring during progenitor and neuronal development in vitro. This is significant as it provides proof-of-concept data that this model may be useful in future efforts to characterise the effects of the loss of FMRP on the development and function of neurons and uncover possible therapeutic targets for early intervention strategies in the future. To the best of our knowledge, the present study is the first to derive live human neural progenitors and differentiated neuron-like cells by direct-to-iNP reprogramming of FXS-patient derived somatic cells. en
dc.publisher ResearchSpace@Auckland en
dc.relation.ispartof Masters Thesis - University of Auckland en
dc.relation.isreferencedby UoA99264935713602091 en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights Restricted Item. Available to authenticated members of The University of Auckland. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Developing a Human Cell Model for Fragile X Syndrome Using Direct Reprogramming en
dc.type Thesis en
thesis.degree.discipline Biomedical Science en
thesis.degree.grantor The University of Auckland en
thesis.degree.level Masters en
dc.rights.holder Copyright: The author en
pubs.elements-id 627564 en
pubs.org-id Faculty of Medical & Hlth Sci en
pubs.org-id Pharmacy en
pubs.record-created-at-source-date 2017-05-30 en


Full text options

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse